top of page
Clinical Study
Safety: Percentage of subjects who experience one or more device-related adverse events within 30-days of successful AVF creation
Efficacy: Percentage of subjects who achieve unassisted maturation without percutaneous and/or surgical intervention through 3-months
To learn more, visit clinicaltrials.gov or email us at clinical@alucentbiomedical.com.
The study plans to enroll up to 30 patients at up to 15 sites in the United States, Australia and Poland.
Primary Endpoints
The ACTIVATE AVF study is evaluating the safety and feasibility of AlucentNVS technology to promote the physiologic and functional maturation of upper-extremity autologous end-to-side AVF in patients with chronic kidney disease (CKD).
bottom of page